Quantifying lesion enhancement on contrast-enhanced mammography: a review of published data

Savaridas, Sarah; Tennant, Sarah

doi:10.1016/j.crad.2021.12.010

Cited by 10 publications

(8 citation statements)

References 31 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result is in line with what has already been published in the literature first by Luczynska et al or by Thomas Knogler et al and then by Chi X et al [ 16 , 21 , 22 ], whose work showed that medium or strong enhancement on CEM was the most likely indicator of malignancy while benign lesions most frequently had a medium or weak enhancement. However, in both our work and in those above-mentioned, the intensity of enhancement was qualitatively evaluated, even though studies with quantitative measurements of intensity in CEM have been published such as those of Ying Liu et al and Rudnicki W et al, whose results, recently supported by Savaridas SL et al, actually confirm the ones of the qualitative studies (i.e., that infiltrating cancers showed the highest values, while benign lesions the lowest) [ 17 , 23 , 24 ].…”

Section: Discussionsupporting

confidence: 69%

“…The internal enhancing pattern was reported as homogeneous for 35/64 (54.68%) and as heterogeneous in the remaining 29 EAs (45%). From the perspective of benignity and malignity of the lesions found, in 13/19 malignancies, the enhancement was more intense and heterogeneous, in contrast to 6/19 of them where the internal pattern was homogeneous; as far as the benignities found, 29 had a homogeneous internal enhancing pattern while 16 had a heterogeneous one [ 16 , 17 ] ( Table 4 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Contrast Enhanced Mammography (CEM) Enhancing Asymmetry: Single-Center First Case Analysis

et al. 2023

View full text Add to dashboard Cite

(1) Purpose: The latest Breast Imaging Reporting and Data System (BI-RADS) lexicon for CEM introduced a new descriptor, enhancing asymmetries (EAs). The purpose of this study was to determine which types of lesions were correlated with EAs. (2) Methods: A total of 3359 CEM exams, executed at AOUC Careggi in Florence, Italy between 2019 and 2021 were retrospectively assessed by two radiologists. For each of the EAs found, the size, the enhancing conspicuity (degree of enhancement relative to background described as low, moderate, or high), whether there was a corresponding finding in the traditional radiology images (US or mammography), the biopsy results when performed including any follow-up exams, and the presence of background parenchymal enhancement (BPE) of the normal breast tissue (minimal, mild, moderate, marked) were described. (3) Results: A total of 64 women were included, 36 of them underwent CEM for a preoperative staging assessment, and 28 for a problem-solving examination. Among the 64 EAs, 19/64 (29.69%) resulted in being category B5 (B5) lesions, 5/64 (7.81%) as category B3 (B3) lesions, and 40/64(62.50%) were negative or benign either after biopsy or second-look exams or follow-up. We assessed that EAs with higher enhancing conspicuity correlated significantly with a higher risk of B5 lesions (p: 0.0071), especially bigger ones (p: 0.0274). Conclusions: EAs can relate both with benign and tumoral lesions, and they need to be assessed as the other CEM descriptors, with re-evaluation of low-energy images and second-look exams, particularly larger EAs with higher enhancing conspicuity.

show abstract

Section: Discussionsupporting

confidence: 69%

Section: Resultsmentioning

confidence: 99%

Contrast Enhanced Mammography (CEM) Enhancing Asymmetry: Single-Center First Case Analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Among these, MRI is very important in the diagnosis of breast cancer. MRI has many advantages, including that it is non-invasive, does not involve exposure to radiation, has high resolution, and can intuitively display the morphological and functional information of breast cancer, which will increase the accuracy of breast cancer diagnosis (14)(15)(16). Numerous studies (17)(18)(19)(20) have found that imaging groups can be used to predict the diagnosis, type, and lymph node metastasis of breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Development of the prediction model based on clinical-imaging omics: molecular typing and sentinel lymph node metastasis of breast cancer

Wang

Zhang

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Imageology uses high-throughput and automatic computing methods to transform medical image data into quantitative data with feature space, and then makes accurate quantitative analysis, extracts features and builds models, which can intuitively observe the overall features of lesions and the surrounding tissues, and provide rich invisible information. At present, the research on the imaging features of dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI) to predict the molecular typing value has achieved results, but the imaging model based on DWI and DCE-magnetic resonance imaging (MRI) is not enough to predict the molecular subtypes, and the prediction value of the prediction model based on the three-dimensional volume of interest of the lesion to the four molecular subtypes of breast cancer has not been fully studied. Methods:The clinical data of 202 breast cancer patients at our hospital from October 2020 to November 2021 were collected. All patients were examined with multimodal MRI before surgery. Base on immunohistochemical recombinant Ki-67 protein (Ki-67), estrogen receptor (ER), human epidermal growth factor receptor-2 (HER-2) and progesterone receptor (PR) results, the tumors were divided into four types According to the results of the sentinel lymph node (SLN) biopsies, the patients were divided into SLN (+) and SLN (−) groups. 3-dimensional (3D) Slicer software was used to outline the region of interest (ROI), and AMni-Kinetics software was used for feature extraction. The imaging characteristics were screened using least absolute shrinkage and selection operator (LASSO)-Logistic regression model using R statistical software, and the receiver operating characteristic (ROC) curve was drawn using "pROC" software package to evaluate the prediction efficiency of the model. Results:The most efficacious model at predicting SLN (+) in breast cancer patients with different molecular subtypes and SLN metastasis was the model based on the imageological characteristics of fat inhibition, and T2-weighted imaging (T2WI), T1-weighted imaging + C (T1WI-C), and DWI combined sequences at the tumor + 2 mm periphery. AUC (sensitivity, specificity) of the validation group were 0.831 (0.856, 0.891), 0.832 (0.660, 0.877), 0.801 (0.772, 0.765), 0.904 (0.769, 0.873), and 0.819 (0.810, 0.500) respectively when the tumor was 2 mm around the tumor. Conclusions:The imaging features extracted from multi-parameter DWI, T1WI+C, and T2WI in breast cancer have certain value at predicting different molecular types and SLNs of breast cancer.^ ORCID: 0000-0001-8656-4461.

show abstract

“…In the last two decades, since the molecular subtyping has become the standard of care in breast cancer management, the role of imaging has been to attempt to find specific imaging features that correlate to certain molecular subtypes with the intention to improve patient survival through prompt diagnosis and treatment [4]. CESM is well tolerated by patients, and its use in clinical practice has increased in the last few years [32]. Published studies have concluded that MRI and CESM have similar accuracy for breast cancer detection [33].…”

Section: Discussionmentioning

confidence: 99%

Mammographic and contrast-enhanced spectral mammography imaging findings of HER2-positive cancers according to hormone receptor status

Elkassas

Helal

Mikhael

et al. 2022

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background Breast cancer is the leading cause of cancer-related mortality in women. Human epidermal growth factor receptor 2 (HER2) overexpression is seen in 20 out of 100 invasive breast cancers. Among HER2+ patients, two distinct hormone receptor (HR) subtypes can be defined: HR-positive (HR+) and HR-negative (HR−) each of which with unique therapeutic response and survival pattern. Contrast-enhanced spectral mammography (CESM) is an emerging novel imaging modality that offers diagnostic performance comparable to contrast-enhanced MRI. The purpose of this retrospective study was to describe the CESM features of HER2+ breast cancers according to hormone receptor status and to assess whether specific mammographic and CESM imaging features can differentiate between HER2+/HR+ and HER2+/HR− breast cancers potentially aiding treatment planning in HER2+ breast cancer patients. Results A total of 61 patients were included. Twenty-nine cases (47.5%) were HER2+/HR+ and 32 cases (52.5%) were HER2+/HR−. No statistically significant difference was found between mammographic imaging presentations and hormonal status. HR- were more likely to be multifocal (P 0.018), rounded or oval (P 0.008), circumscribed (P 0.004), and with associated non-mass enhancement (NME) (P < 0.001). HR+ cancers showed a tendency for irregular shape (P 0.008), spiculated outline (P 0.004), and heterogeneous (P 0.021) or ring (P 0.046) enhancement. Conclusions HER2+ tumors have different demographic, pathologic and imaging features according to the hormone receptor status. Because the two subtypes of HER2 breast cancer have different clinical outcomes, CESM imaging features can potentially enhance patient outcome by accelerating the diagnosis and treatment.

show abstract

Quantifying lesion enhancement on contrast-enhanced mammography: a review of published data

Cited by 10 publications

References 31 publications

Contrast Enhanced Mammography (CEM) Enhancing Asymmetry: Single-Center First Case Analysis

Contrast Enhanced Mammography (CEM) Enhancing Asymmetry: Single-Center First Case Analysis

Development of the prediction model based on clinical-imaging omics: molecular typing and sentinel lymph node metastasis of breast cancer

Mammographic and contrast-enhanced spectral mammography imaging findings of HER2-positive cancers according to hormone receptor status

Contact Info

Product

Resources

About